Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Aug. 31, 2025	Aug. 31, 2024
Cash flows from operating activities:
Net income	$ 1,388,048	$ 2,263,710
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense	742,231	444,850
Impairment of investment - Tianhe stock	0	308,000
Loss on sale of property and equipment	48,304	0
Losses (gains) on marketable securities	604,619	(1,056,052)
Unrealized gain on interest rate swap contract	0	(105,887)
Compensatory element of stock options	374,198	631,435
Provision for doubtful accounts	780,197	918,488
Amortization of debt issuance costs	15,657	15,967
Amortization of operating lease right-of-use asset	295,654	237,299
Changes in assets and liabilities:
Accounts receivable	(304,483)	(1,215,889)
Prepaid expenses	19,125	102,898
Inventory	79,730	209,209
Other current assets	109,604	(26,529)
Deposits and other assets, net	(92,144)	(51,553)
Accounts payable	741,407	(293,685)
Accrued expenses	(3,525,297)	(2,490,236)
Operating lease liability	(317,744)	(175,633)
Other liabilities	0	3,829
Deferred revenue	3,238,687	4,133,696
Net cash from operating activities	4,197,793	3,853,917
Cash flows from investing activities:
Purchases of property and equipment	(163,249)	(2,395,360)
Sale of property and equipment	115,000	0
Payment of Duke license agreement	0	(1,066,667)
Proceeds from liquidation of marketable securities	0	101,873
Purchases of marketable securities	(3,160,145)	(1,759,828)
Sale of marketable securities	2,522,711	1,358,732
Net cash used in investing activities	(685,683)	(3,761,250)
Cash flows used in financing activities:
Treasury stock purchases	(169,502)	(1,423,871)
Repayments of note payable	(110,235)	(106,428)
Repayment of line of credit	(7,120,000)	(2,200,000)
Proceeds from the exercise of stock options	23,101	1,002
Proceeds from line of credit	6,800,000	3,200,000
Dividends paid	(3,231,227)	0
Proceeds from Swap termination	0	228,000
Net cash used in financing activities	(3,807,863)	(301,297)
Decrease in cash and cash equivalents	(295,753)	(208,630)
Cash and cash equivalents - beginning of period	560,960	406,067
Cash and cash equivalents - end of period	265,207	197,437
Supplemental non cash operating activities
Lease liability arising from right-of-use asset	396,163	100,932
Supplemental investing activities:
Construction costs payable	0	(880,348)
Supplemental cash flow information
Interest	1,533,485	1,482,909
Income taxes	$ 2,833,737	$ 2,385,096

CRYO CELL INTERNATIONAL INC 10-Q